Can next-generation antibodies offset biosimilar competition?
Nature Reviews Drug Discovery 11,426 (2012).
doi:10.1038/nrd3749
Author:Asher Mullard
With the first biosimilar version of a monoclonal antibody now under regulatory review in the European Union,which R&D strategies are innovators relying on to counteract competition?
Nature Reviews Drug Discovery –Issue –nature.com science feeds












































